Form 4 for SCLX Scilex Holding Co
Accepted 2025-01-17 00:00:00 ET · period of report 2025-01-16 · accession 0000950170-25-006876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-17 | 2025-01-16 | SCLX | SCLX Stock Acquisition JV LLC | 10% | J - Other | — | -779.4K | 54.29M | -1% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-16 | J | D | 779,371 | — | 54,289,214 | D | — | — | (F1) Transferred in connection with a First Amendment to License and Commercialization Agreement (the "License Amendment") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the "Transfer Agreement"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person. |